• ProChon Biotech Ltd., of Woburn, Mass., added Jack Farr to its scientific advisory board.

• Regenicin Inc., of New York, added Christopher A. Hadsall as chief operating officer.

• Resverlogix Corp., of Calgary, Alberta, named Kenneth Zuerblis to its board.

• Roche, of Nutley, N.J., named Jacques Banchereau senior vice president and head of the inflammation and virology discovery and translational areas.

• Sequenom Inc., of San Diego, formed a clinical advisory board with three initial members: Gregory S. Hageman, Jeffrey S. Heier and Karen Gehrs.

• Sernova Corp., of London, Ontario, appointed David Sutherland to its scientific advisory board.

• Spectrum Pharmaceuticals Inc., of Irvine, Calif., appointed Brett L. Scott senior vice president and acting chief financial officer.

• Stem Cell Therapeutics Corp., of Calgary, Alberta, appointed Michael Cook chief financial officer.

• Tengion Inc., of East Norriton, appointed Richard E. Kuntz to its board.

• Tetraphase Pharmaceuticals Inc., of Watertown, Mass., appointed Garen Bohlin to its board.

• Transdel Pharmaceuticals Inc., of La Jolla, Calif., appointed John N. Bonfiglio president and CEO.

• Transgenomic Inc., of Omaha, Neb., named Eric Johnson medical director for laboratory services.

• YM BioSciences Inc., of Mississauga, Ontario, named Nick Glover CEO, effective Nov. 18.